H1 revenues increased by a strong 39% to £27.6m, within which recurring software revenues increased by over 60% as management continues to focus on higher margin activities. Whilst wage inflation held back H1 profit growth as previously discussed, price increases will support H2. Market conditions in pharma R&D are robust, with demand for Instem’s solutions remaining high. Visibility for H2 has increased, meaning trading for the full year is reported to be in line with expectations. We make no c ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 update – in line for FY
- Published:
04 Aug 2022 -
Author:
Chris Glasper -
Pages:
3
H1 revenues increased by a strong 39% to £27.6m, within which recurring software revenues increased by over 60% as management continues to focus on higher margin activities. Whilst wage inflation held back H1 profit growth as previously discussed, price increases will support H2. Market conditions in pharma R&D are robust, with demand for Instem’s solutions remaining high. Visibility for H2 has increased, meaning trading for the full year is reported to be in line with expectations. We make no c ....